ClinicalTrials.gg
CompletedNCT04881760Updated Sep 13, 2023Results posted

A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

A Phase 2 interventional study of LY3437943 and Placebo in Obesity and Overweight, sponsored by Eli Lilly and Company. Completed at 28 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-13.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
338
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing retatrutide in Obesity — 1 open to participants now, 6 under way, 5 of them phase 3. retatrutide · Obesity.

Enrollment
9th of 16
338 · median 392
Started
2021
the only one that year
Phase 2
3 of 16
1 open now
Registered
1st of 16
by date
Lead sponsor
15 of 16
Eli Lilly and Company

Among the 16 studies testing retatrutide in Obesity, this one is the 9th largest by enrollment, is the only one that started in 2021, is one of 3 in phase 2, and was the 1st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

1 of the 16 studies testing retatrutide in Obesity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About retatrutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing retatrutide in Obesity, or all of them as a file.
02

Study summary

This is a study of LY3437943 in participants who have obesity or are overweight. The main purpose is to learn more about how LY3437943 affects body weight loss. The study will last about 18 months and may include up to 18 visits.

03

Conditions studied

  • Obesity
  • Overweight

Keywords

  • Nutritional or Metabolism Disorder
  • Weight Loss
  • Overnutrition
  • Incretins
  • Hormones
  • Physiological Effects of Drugs
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a (BMI) ) ≥30 and ≤50 kilograms per square meter (kg/m²), or ≥27 kg/m² and \<30 kg/m², with at least one of the following comorbidities: hypertension, dyslipidemia, cardiovascular disease
  • Participants must be willing to learn how to self-inject study drug or receive an injection from a trained individual if visually impaired or with physical limitations, and follow study procedures for the duration of the study, including, but not limited to, follow lifestyle advice (for example, dietary changes and physical activity plan), maintain a study drug administration log, and complete required questionnaires

Exclusion criteria

Exclusion Criteria:

  • Participants must not have type 1 or type 2 diabetes mellitus
  • Participants must not have had an increase or decrease in body weight > more than 5 kg (11 pounds) within the past 3 months
  • Participants must not have had surgery for obesity or plan to have such surgery during the study
  • Participants must not be using medications that promote weight loss or cause weight gain
  • Participants must not drink excessive amounts of alcohol (more than 14 units a week for women or more than 21 units a week for men)
  • Participants must not have used marijuana within the last 3 months.
  • Participants must not have heart attack, stroke, or hospitalization for congestive heart failure in the past 3 months
  • Participants must not have active cancer within the last 5 years
  • Participants must not have uncontrolled high blood pressure
  • Participants must not have liver disease other than non-alcoholic fatty liver disease
  • Participants must not have renal impairment with estimated (eGFR) \<45 mL/min/1.73 m2
  • Participants must not have a history of acute or chronic pancreatitis symptomatic gallbladder disease or documented infection
  • Participants must not have a major problem with depression or other mental illness within the last 2 years
  • Participants must not have family or personal history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma (family is defined as a first degree relative)
  • Female participants must not be pregnant, breast-feeding, or intend to become pregnant or of and not using adequate method (adequate contraceptive measures as required by local regulation or practice)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
338 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo matched to LY3437943 administered as subcutaneous (SC) injection once-weekly (QW).

    Drug: Placebo

  • Experimental
    1 milligram (mg) LY3437943

    Participants received 1 mg LY3437943 administered as SC injection QW.

    Drug: LY3437943

  • Experimental
    4 mg LY3437943 (2 mg)

    Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.

    Drug: LY3437943

  • Experimental
    4 mg LY3437943

    Participants received 4 mg LY3437943 administered as SC injection QW.

    Drug: LY3437943

  • Experimental
    8 mg LY3437943 (2 mg)

    Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.

    Drug: LY3437943

  • Experimental
    8 mg LY3437943 (4 mg)

    Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.

    Drug: LY3437943

  • Experimental
    12 mg LY3437943 (2 mg)

    Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW.

    Drug: LY3437943

Interventions

  • Administered SC

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Mean Percent Change From Baseline in Body Weight

    Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Mean Percent Change From Baseline in Body Weight

    LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.

    Time frame: Baseline, Week 48

  2. Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction

    Percentage of participants who achieve ≥ 5% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<36 kilograms per square meter (kg/m2), ≥36 kg/m2\] and sex \[female, male\] as fixed effects, and baseline body weight as a covariate.

    Time frame: Week 24

  3. Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction

    Percentage of participants who achieve ≥ 5% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<36 kg/m2, ≥36 kg/m2\] and sex \[female, male\] as fixed effects, and baseline body weight as a covariate.

    Time frame: Week 48

  4. Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction

    Percentage of participants who achieve ≥ 10% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<36 kg/m2, ≥36 kg/m2\] and sex \[female, male\] as fixed effects, and baseline body weight as a covariate.

    Time frame: Week 24

  5. Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction

    Percentage of participants who achieve ≥ 10% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<36 kg/m2, ≥36 kg/m2\] and sex \[female, male\] as fixed effects, and baseline body weight as a covariate.

    Time frame: Week 48

  6. Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction

    Percentage of participants who achieve ≥ 15% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<36 kg/m2, ≥36 kg/m2\] and sex \[female, male\] as fixed effects, and baseline body weight as a covariate.

    Time frame: Week 24

  7. Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction

    Percentage of participants who achieve ≥ 15% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<36 kg/m2, ≥36 kg/m2\] and sex \[female, male\] as fixed effects, and baseline body weight as a covariate.

    Time frame: Week 48

  8. Mean Change From Baseline in Body Weight

    LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.

    Time frame: Baseline, Week 24

  9. Mean Change From Baseline in Body Weight

    LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.

    Time frame: Baseline, Week 48

  10. Mean Change From Baseline in BMI

    LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.

    Time frame: Baseline, Week 24

  11. Mean Change From Baseline in BMI

    LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.

    Time frame: Baseline, Week 48

  12. Mean Change From Baseline in Waist Circumference

    LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.

    Time frame: Baseline, Week 24

  13. Mean Change From Baseline in Waist Circumference

    LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.

    Time frame: Baseline, Week 48

07

Results

Posted Sep 13, 2023

Participant flow

Participant flow — Overall Study
MilestonePlacebo1 mg LY34379434 mg LY3437943 (2 mg)4 mg LY34379438 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Started70693334353562
Received at least one dose of study drug70693333353562
Completed50602626302954
Not completed20978568
Withdrew: Adverse event0110112
Withdrew: Death0001000
Withdrew: Lost to follow-up5751244
Withdrew: Withdrawal by subject13114212
Withdrew: Randomized but never treated0001000
Withdrew: Inadvertent enrollment2000000
Withdrew: Site closure0001000

Outcome measures

PrimaryMean Percent Change From Baseline in Body Weight

Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percent change
Mean Percent Change From Baseline in Body Weight
percent changePlacebo1 mg LY34379434 mg LY3437943 (2 mg)4 mg LY34379438 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Mean Percent Change From Baseline in Body Weight-1.55 ± 0.54-7.18 ± 0.67-12.00 ± 0.71-13.80 ± 0.97-16.64 ± 0.74-18.26 ± 0.95-17.39 ± 0.69
Statistical analysis
  • Placebo vs 1 mg LY3437943 · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -5.64 · 95% CI -7.34 to -3.94
  • Placebo vs 4 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -10.45 · 95% CI -12.21 to -8.70
  • Placebo vs 4 mg LY3437943 · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -12.25 · 95% CI -14.42 to -10.08
  • Placebo vs 8 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -15.10 · 95% CI -16.90 to -13.30
  • Placebo vs 8 mg LY3437943 (4 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -16.72 · 95% CI -18.86 to -14.58
  • Placebo vs 12 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -15.85 · 95% CI -17.57 to -14.13
SecondaryMean Percent Change From Baseline in Body Weight

LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · percent change
Mean Percent Change From Baseline in Body Weight
percent changePlacebo1 mg LY34379434 mg LY3437943 (2 mg)4 mg LY34379438 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Mean Percent Change From Baseline in Body Weight-2.11 ± 0.73-8.67 ± 0.95-16.32 ± 1.58-17.83 ± 1.53-21.72 ± 1.41-23.88 ± 1.51-24.22 ± 1.24
Statistical analysis
  • Placebo vs 1 mg LY3437943 · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -6.57 · 95% CI -8.94 to -4.20
  • Placebo vs 4 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -14.21 · 95% CI -17.64 to -10.78
  • Placebo vs 4 mg LY3437943 · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -15.72 · 95% CI -19.05 to -12.40
  • Placebo vs 8 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -19.62 · 95% CI -22.73 to -16.51
  • Placebo vs 8 mg LY3437943 (4 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -21.78 · 95% CI -25.05 to -18.51
  • Placebo vs 12 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -22.11 · 95% CI -24.92 to -19.31
SecondaryPercentage of Participants Who Achieve ≥ 5% Body Weight Reduction

Percentage of participants who achieve ≥ 5% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<36 kilograms per square meter (kg/m2), ≥36 kg/m2\] and sex \[female, male\] as fixed effects, and baseline body weight as a covariate.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction
percentage of participantsPlacebo1 mg LY34379434 mg LY3437943 (2 mg)4 mg LY34379438 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction2659879410010097
Statistical analysis
  • Placebo vs 1 mg LY3437943 · Regression, Logistic · p = <0.001 · Risk difference (rd): 33 · 95% CI 17 to 49
  • Placebo vs 4 mg LY3437943 (2 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 61 · 95% CI 45 to 77
  • Placebo vs 4 mg LY3437943 · Regression, Logistic · p = <0.001 · Risk difference (rd): 68 · 95% CI 54 to 81
  • Placebo vs 8 mg LY3437943 (2 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 74 · 95% CI 63 to 85
  • Placebo vs 8 mg LY3437943 (4 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 74 · 95% CI 63 to 85
  • Placebo vs 12 mg LY3437943 (2 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 71 · 95% CI 59 to 82
SecondaryPercentage of Participants Who Achieve ≥ 5% Body Weight Reduction

Percentage of participants who achieve ≥ 5% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<36 kg/m2, ≥36 kg/m2\] and sex \[female, male\] as fixed effects, and baseline body weight as a covariate.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction
percentage of participantsPlacebo1 mg LY34379434 mg LY3437943 (2 mg)4 mg LY34379438 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction27648797100100100
Statistical analysis
  • Placebo vs 1 mg LY3437943 · Regression, Logistic · p = <0.001 · Risk difference (rd): 37 · 95% CI 20 to 54
  • Placebo vs 4 mg LY3437943 (2 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 60 · 95% CI 44 to 76
  • Placebo vs 4 mg LY3437943 · Regression, Logistic · p = <0.001 · Risk difference (rd): 70 · 95% CI 57 to 83
  • Placebo vs 8 mg LY3437943 (2 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 73 · 95% CI 62 to 84
  • Placebo vs 8 mg LY3437943 (4 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 73 · 95% CI 62 to 84
  • Placebo vs 12 mg LY3437943 (2 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 73 · 95% CI 67 to 84
SecondaryPercentage of Participants Who Achieve ≥ 10% Body Weight Reduction

Percentage of participants who achieve ≥ 10% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<36 kg/m2, ≥36 kg/m2\] and sex \[female, male\] as fixed effects, and baseline body weight as a covariate.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction
percentage of participantsPlacebo1 mg LY34379434 mg LY3437943 (2 mg)4 mg LY34379438 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction3255972839490
Statistical analysis
  • Placebo vs 1 mg LY3437943 · Regression, Logistic · p = <0.001 · Risk difference (rd): 22 · 95% CI 11 to 33
  • Placebo vs 4 mg LY3437943 (2 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 56 · 95% CI 38 to 73
  • Placebo vs 4 mg LY3437943 · Regression, Logistic · p = <0.001 · Risk difference (rd): 69 · 95% CI 53 to 85
  • Placebo vs 8 mg LY3437943 (2 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 80 · 95% CI 66 to 93
  • Placebo vs 8 mg LY3437943 (4 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 91 · 95% CI 83 to 100
  • Placebo vs 12 mg LY3437943 (2 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 87 · 95% CI 78 to 96
SecondaryPercentage of Participants Who Achieve ≥ 10% Body Weight Reduction

Percentage of participants who achieve ≥ 10% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<36 kg/m2, ≥36 kg/m2\] and sex \[female, male\] as fixed effects, and baseline body weight as a covariate.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction
percentage of participantsPlacebo1 mg LY34379434 mg LY3437943 (2 mg)4 mg LY34379438 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction9277376909193
Statistical analysis
  • Placebo vs 1 mg LY3437943 · Regression, Logistic · p = 0.008 · Risk difference (rd): 18 · 95% CI 5 to 31
  • Placebo vs 4 mg LY3437943 (2 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 64 · 95% CI 48 to 81
  • Placebo vs 4 mg LY3437943 · Regression, Logistic · p = <0.001 · Risk difference (rd): 67 · 95% CI 51 to 84
  • Placebo vs 8 mg LY3437943 (2 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 81 · 95% CI 69 to 94
  • Placebo vs 8 mg LY3437943 (4 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 82 · 95% CI 71 to 94
  • Placebo vs 12 mg LY3437943 (2 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 84 · 95% CI 74 to 94
SecondaryPercentage of Participants Who Achieve ≥ 15% Body Weight Reduction

Percentage of participants who achieve ≥ 15% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<36 kg/m2, ≥36 kg/m2\] and sex \[female, male\] as fixed effects, and baseline body weight as a covariate.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction
percentage of participantsPlacebo1 mg LY34379434 mg LY3437943 (2 mg)4 mg LY34379438 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction1102944516870
Statistical analysis
  • Placebo vs 1 mg LY3437943 · Regression, Logistic · p = 0.029 · Risk difference (rd): 9 · 95% CI 1 to 17
  • Placebo vs 4 mg LY3437943 (2 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 27 · 95% CI 11 to 43
  • Placebo vs 4 mg LY3437943 · Regression, Logistic · p = <0.001 · Risk difference (rd): 43 · 95% CI 26 to 60
  • Placebo vs 8 mg LY3437943 (2 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 49 · 95% CI 33 to 66
  • Placebo vs 8 mg LY3437943 (4 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 67 · 95% CI 51 to 83
  • Placebo vs 12 mg LY3437943 (2 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 68 · 95% CI 56 to 80
SecondaryPercentage of Participants Who Achieve ≥ 15% Body Weight Reduction

Percentage of participants who achieve ≥ 15% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<36 kg/m2, ≥36 kg/m2\] and sex \[female, male\] as fixed effects, and baseline body weight as a covariate.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction
percentage of participantsPlacebo1 mg LY34379434 mg LY3437943 (2 mg)4 mg LY34379438 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction2165564737783
Statistical analysis
  • Placebo vs 1 mg LY3437943 · Regression, Logistic · p = 0.002 · Risk difference (rd): 15 · 95% CI 6 to 24
  • Placebo vs 4 mg LY3437943 (2 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 53 · 95% CI 36 to 70
  • Placebo vs 4 mg LY3437943 · Regression, Logistic · p = <0.001 · Risk difference (rd): 63 · 95% CI 47 to 79
  • Placebo vs 8 mg LY3437943 (2 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 71 · 95% CI 55 to 87
  • Placebo vs 8 mg LY3437943 (4 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 75 · 95% CI 62 to 89
  • Placebo vs 12 mg LY3437943 (2 mg) · Regression, Logistic · p = <0.001 · Risk difference (rd): 82 · 95% CI 71 to 92
SecondaryMean Change From Baseline in Body Weight

LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · kilograms (kg)
Mean Change From Baseline in Body Weight
kilograms (kg)Placebo1 mg LY34379434 mg LY3437943 (2 mg)4 mg LY34379438 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Mean Change From Baseline in Body Weight-1.27 ± 0.63-7.72 ± 0.73-12.59 ± 0.81-14.79 ± 1.09-17.70 ± 0.79-19.75 ± 1.08-18.53 ± 0.71
Statistical analysis
  • Placebo vs 1 mg LY3437943 · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -6.46 · 95% CI -8.36 to -4.56
  • Placebo vs 4 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -11.32 · 95% CI -13.34 to -9.30
  • Placebo vs 4 mg LY3437943 · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -13.52 · 95% CI -15.99 to -11.05
  • Placebo vs 8 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -16.43 · 95% CI -18.41 to -14.45
  • Placebo vs 8 mg LY3437943 (4 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -18.48 · 95% CI -20.93 to -16.04
  • Placebo vs 12 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -17.26 · 95% CI -19.11 to -15.40
SecondaryMean Change From Baseline in Body Weight

LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · kg
Mean Change From Baseline in Body Weight
kgPlacebo1 mg LY34379434 mg LY3437943 (2 mg)4 mg LY34379438 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Mean Change From Baseline in Body Weight-1.84 ± 0.83-9.37 ± 1.06-17.32 ± 1.78-19.13 ± 1.80-23.52 ± 1.61-25.88 ± 1.68-26.17 ± 1.33
Statistical analysis
  • Placebo vs 1 mg LY3437943 · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -7.53 · 95% CI -10.18 to -4.88
  • Placebo vs 4 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -15.48 · 95% CI -19.35 to -11.60
  • Placebo vs 4 mg LY3437943 · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -17.29 · 95% CI -21.19 to -13.39
  • Placebo vs 8 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -21.69 · 95% CI -25.25 to -18.12
  • Placebo vs 8 mg LY3437943 (4 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -24.04 · 95% CI -27.72 to -20.36
  • Placebo vs 12 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -24.34 · 95% CI -27.40 to -21.27
SecondaryMean Change From Baseline in BMI

LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · kg/m^2
Mean Change From Baseline in BMI
kg/m^2Placebo1 mg LY34379434 mg LY3437943 (2 mg)4 mg LY34379438 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Mean Change From Baseline in BMI-0.49 ± 0.21-2.64 ± 0.26-4.47 ± 0.28-5.13 ± 0.36-6.15 ± 0.27-6.84 ± 0.36-6.44 ± 0.25
Statistical analysis
  • Placebo vs 1 mg LY3437943 · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -2.15 · 95% CI -2.80 to -1.50
  • Placebo vs 4 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -3.98 · 95% CI -4.66 to -3.29
  • Placebo vs 4 mg LY3437943 · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -4.64 · 95% CI -5.46 to -3.82
  • Placebo vs 8 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -5.66 · 95% CI -6.34 to -4.99
  • Placebo vs 8 mg LY3437943 (4 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -6.35 · 95% CI -7.17 to -5.53
  • Placebo vs 12 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -5.95 · 95% CI -6.59 to -5.32
SecondaryMean Change From Baseline in BMI

LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · kg/m^2
Mean Change From Baseline in BMI
kg/m^2Placebo1 mg LY34379434 mg LY3437943 (2 mg)4 mg LY34379438 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Mean Change From Baseline in BMI-0.72 ± 0.29-3.22 ± 0.37-6.14 ± 0.65-6.67 ± 0.59-8.12 ± 0.55-9.02 ± 0.57-9.14 ± 0.46
Statistical analysis
  • Placebo vs 1 mg LY3437943 · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -2.50 · 95% CI -3.42 to -1.57
  • Placebo vs 4 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -5.42 · 95% CI -6.81 to -4.03
  • Placebo vs 4 mg LY3437943 · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -5.95 · 95% CI -7.23 to -4.67
  • Placebo vs 8 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -7.40 · 95% CI -8.62 to -6.18
  • Placebo vs 8 mg LY3437943 (4 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -8.30 · 95% CI -9.55 to -7.05
  • Placebo vs 12 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -8.42 · 95% CI -9.49 to -7.35
SecondaryMean Change From Baseline in Waist Circumference

LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · centimeters (cm)
Mean Change From Baseline in Waist Circumference
centimeters (cm)Placebo1 mg LY34379434 mg LY3437943 (2 mg)4 mg LY34379438 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Mean Change From Baseline in Waist Circumference-2.60 ± 0.80-5.43 ± 0.94-10.33 ± 1.05-12.55 ± 1.00-13.74 ± 1.04-14.99 ± 0.98-14.33 ± 0.86
Statistical analysis
  • Placebo vs 1 mg LY3437943 · Mixed Models Analysis · p = 0.022 · Ls mean difference (final values): -2.82 · 95% CI -5.23 to -0.41
  • Placebo vs 4 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -7.73 · 95% CI -10.32 to -5.13
  • Placebo vs 4 mg LY3437943 · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -9.95 · 95% CI -12.47 to -7.43
  • Placebo vs 8 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -11.14 · 95% CI -13.72 to -8.56
  • Placebo vs 8 mg LY3437943 (4 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -12.38 · 95% CI -14.87 to -9.90
  • Placebo vs 12 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -11.73 · 95% CI -14.04 to -9.43
SecondaryMean Change From Baseline in Waist Circumference

LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · cm
Mean Change From Baseline in Waist Circumference
cmPlacebo1 mg LY34379434 mg LY3437943 (2 mg)4 mg LY34379438 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
Mean Change From Baseline in Waist Circumference-2.64 ± 0.99-6.49 ± 1.12-14.58 ± 1.56-14.87 ± 1.73-18.53 ± 1.46-18.50 ± 1.52-19.60 ± 1.29
Statistical analysis
  • Placebo vs 1 mg LY3437943 · Mixed Models Analysis · p = 0.010 · Ls mean difference (final values): -3.84 · 95% CI -6.77 to -0.91
  • Placebo vs 4 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -11.94 · 95% CI -15.54 to -8.33
  • Placebo vs 4 mg LY3437943 · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -12.22 · 95% CI -16.11 to -8.33
  • Placebo vs 8 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -15.88 · 95% CI -19.33 to -12.43
  • Placebo vs 8 mg LY3437943 (4 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -15.85 · 95% CI -19.39 to -12.31
  • Placebo vs 12 mg LY3437943 (2 mg) · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -16.95 · 95% CI -20.13 to -13.78

Adverse events

Collected over Baseline Through End of Safety Follow-up (Up to 52 Weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/70 (0%)3/70 (4.3%)40/70 (57.1%)
1 mg LY34379430/69 (0%)3/69 (4.3%)46/69 (66.7%)
4 mg LY3437943 (2 mg)0/33 (0%)0/33 (0%)22/33 (66.7%)
4 mg LY34379431/33 (3%)2/33 (6.1%)24/33 (72.7%)
8 mg LY3437943 (2 mg)0/35 (0%)1/35 (2.9%)26/35 (74.3%)
8 mg LY3437943 (4 mg)0/35 (0%)2/35 (5.7%)31/35 (88.6%)
12 mg LY3437943 (2 mg)0/62 (0%)2/62 (3.2%)52/62 (83.9%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventPlacebo1 mg LY34379434 mg LY3437943 (2 mg)4 mg LY34379438 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
DrowningGeneral disorders0/700/690/331/330/350/350/62
Clear cell renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/700/690/331/330/350/350/62
Cerebrovascular accidentNervous system disorders0/702/690/330/330/350/350/62
Cardiac failureCardiac disorders0/700/690/330/331/350/350/62
VomitingGastrointestinal disorders0/700/690/330/330/351/350/62
Cholecystitis acuteHepatobiliary disorders0/700/690/330/330/351/350/62
Covid-19Infections and infestations0/700/690/330/330/351/350/62
Acute kidney injuryRenal and urinary disorders0/700/690/330/330/351/350/62
Pancreatitis acuteGastrointestinal disorders0/700/690/330/330/350/351/62
Electrocardiogram qt prolongedInvestigations0/700/690/330/330/350/351/62
Most frequent other events
Showing 10 of 35
Most frequent other events
EventPlacebo1 mg LY34379434 mg LY3437943 (2 mg)4 mg LY34379438 mg LY3437943 (2 mg)8 mg LY3437943 (4 mg)12 mg LY3437943 (2 mg)
NauseaGastrointestinal disorders8/7010/696/3312/336/3521/3528/62
Covid-19Infections and infestations14/7013/694/336/336/3511/3515/62
Decreased appetiteMetabolism and nutrition disorders6/709/696/338/334/3511/3518/62
VomitingGastrointestinal disorders1/702/694/334/332/359/3512/62
DiarrhoeaGastrointestinal disorders8/706/694/334/337/357/359/62
ConstipationGastrointestinal disorders2/705/695/332/334/354/3510/62
FatigueGeneral disorders3/703/694/332/331/353/356/62
HeadacheNervous system disorders0/702/691/330/330/354/354/62
Early satietyGeneral disorders4/703/691/331/330/352/356/62
Gastrooesophageal reflux diseaseGastrointestinal disorders1/701/692/333/333/350/354/62

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Placebo1 mg LY34379434 mg LY3437943 (2 mg)4 mg LY34379438 mg LY3437943 (2 mg)8 mg LY343794 (4 mg)12 mg LY3437943 (2 mg)Total
Mean48.00 ± 12.5450.60 ± 13.3050.80 ± 11.8846.80 ± 14.1046.10 ± 13.5248.70 ± 11.1445.80 ± 12.1848.20 ± 12.73
Sex: Female, Male
Sex: Female, Male(Participants)Placebo1 mg LY34379434 mg LY3437943 (2 mg)4 mg LY34379438 mg LY3437943 (2 mg)8 mg LY343794 (4 mg)12 mg LY3437943 (2 mg)Total
Female34331616171730163
Male36361718181832175
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo1 mg LY34379434 mg LY3437943 (2 mg)4 mg LY34379438 mg LY3437943 (2 mg)8 mg LY343794 (4 mg)12 mg LY3437943 (2 mg)Total
Hispanic or Latino2223914151222117
Not Hispanic or Latino47462420202340220
Unknown or Not Reported10000001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo1 mg LY34379434 mg LY3437943 (2 mg)4 mg LY34379438 mg LY3437943 (2 mg)8 mg LY343794 (4 mg)12 mg LY3437943 (2 mg)Total
American Indian or Alaska Native00010012
Asian20001014
Native Hawaiian or Other Pacific Islander01000001
Black or African American864241227
White59612930303356298
More than one race10010125
Unknown or Not Reported01000001
Region of Enrollment
Region of Enrollment(participants)Placebo1 mg LY34379434 mg LY3437943 (2 mg)4 mg LY34379438 mg LY3437943 (2 mg)8 mg LY343794 (4 mg)12 mg LY3437943 (2 mg)Total
United States70693334353562338
Baseline Body Weight
Baseline Body Weight(kilograms (kg))Placebo1 mg LY34379434 mg LY3437943 (2 mg)4 mg LY34379438 mg LY3437943 (2 mg)8 mg LY343794 (4 mg)12 mg LY3437943 (2 mg)Total
Mean109.21 ± 20.88106.36 ± 19.84108.04 ± 26.31107.01 ± 21.29106.50 ± 21.55108.63 ± 20.88107.97 ± 21.69107.73 ± 21.35
Baseline Body Mass Index (BMI)
Baseline Body Mass Index (BMI)(kilograms per meter squared (kg/m^2))Placebo1 mg LY34379434 mg LY3437943 (2 mg)4 mg LY34379438 mg LY3437943 (2 mg)8 mg LY343794 (4 mg)12 mg LY3437943 (2 mg)Total
Mean37.31 ± 5.9037.49 ± 5.8537.27 ± 5.8737.39 ± 4.6637.37 ± 6.0436.96 ± 5.4937.42 ± 5.9837.34 ± 5.71
08

Study locations

28 sites
  • Perseverance Research Center
    Scottsdale, Arizona 85254, United States
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Valley Research
    Fresno, California 93720, United States
  • Velocity Clinical Research, Huntington Park
    Huntington Park, California 90255, United States
  • Velocity Clinical Research, Huntington Park
    Los Angeles, California 90057, United States
  • Southern California Dermatology, Inc.
    Santa Ana, California 92701, United States
  • Coastal Metabolic Research Centre
    Ventura, California 93003, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • East Coast Institute for Research, LLC
    Jacksonville, Florida 32216, United States
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34652, United States
  • Encore Medical Research - Weston
    Weston, Florida 33331, United States
  • Springfield Diabetes & Endocrine Center
    Springfield, Illinois 62711, United States
  • Cotton O'Neil Diabetes and Endocrinology Center
    Topeka, Kansas 66606, United States
  • Tandem Clinical Research,LLC
    Marrero, Louisiana 70072, United States
  • StudyMetrix Research
    Saint Peters, Missouri 63303, United States
  • Amici Clinical Research LLC
    Raritan, New Jersey 08869, United States
  • Intend Research, LLC
    Norman, Oklahoma 73069, United States
  • Allegheny Endocrinology Associates
    Pittsburgh, Pennsylvania 15212, United States
  • New Phase Research and Development
    Knoxville, Tennessee 37909, United States
  • Texas Diabetes & Endocrinology, P.A.
    Austin, Texas 78731, United States
  • Dallas Diabetes Research Center
    Dallas, Texas 75230, United States
  • Juno Research
    Houston, Texas 77054, United States
  • Endocrine Ips, Pllc
    Houston, Texas 77079, United States
  • Southern Endocrinology Associates
    Mesquite, Texas 75149, United States
  • Rainier Clinical Research Center
    Renton, Washington 98057, United States
  • Private Practice - Dr. Paola Mansilla-Letelier
    Guaynabo, 00970, Puerto Rico
  • GCM Medical Group, PSC - Hato Rey Site
    San Juan, 00917, Puerto Rico
  • San Juan City Hospital
    San Juan, 00935, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in May 2022, 11 months.

Results were first posted in Sep 2023, 1 year 3 months after primary completion. A results delay was requested in May 2023.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 11 months is close to that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2021
First posted
May 11, 2021
StartActual
May 20, 2021
Primary completionActual
May 16, 2022
CompletionActual
Nov 22, 2022
Results delay requested
May 10, 2023
Results first posted
Sep 13, 2023
Last update
Sep 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04881760
Responsible party
Sponsor
First posted
May 11, 2021
Start date
May 20, 2021
Primary completion
May 16, 2022
Completion
Nov 22, 2022
Results posted
Sep 13, 2023
Last update
Sep 13, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Retatrutide

Start the discussion